Saltrol Drug Interactions

Inhibitors of Cytochrome P450 3A4: Salmeterol and Fluticasone propionate are substrates of CYP3A4. The use of strong CYP3A4 inhibitors is not recommended because increased systemic corticosteroid and increased cardiovascular adverse effects may occur.
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Salmeterol and Fluticasone propionate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, because the action of Salmeterol on the vascular system may be potentiated by these agents.
β Adrenergic Receptor Blocking Agents: β adrenergic blockers may weaken or antagonize the effect of Salmeterol. Both non-selective and selective β blockers should be avoided in patients with asthma. Potentially serious hypokalemia may result from β₂ agonist therapy. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids and diuretics.
Non-Potassium-Sparing Diuretics: The ECG changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β agonists, such as salmeterol, especially when the recommended dose of the β agonist is exceeded. Caution is advised in the co-administration of Salmeterol + Fluticasone propionate with non-potassium-sparing diuretics.